The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Contemporary Prevalence of Gout & Hyperuricemia in the U.S.

Contemporary Prevalence of Gout & Hyperuricemia in the U.S.

May 31, 2019 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Gout is an inflammatory arthritis triggered by the crystallization of monosodium urate monohydrate inside the joints. It’s preceded by hyperuricemia. Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and economic productivity loss. Further, gout is strongly associated with metabolic syndrome and may contribute to myocardial infarction, type 2 diabetes mellitus, chronic kidney disease and premature mortality. The prevalence of gout and hyperuricemia in the U.S. more than doubled between the 1960s and the 1990s and continued to increase steadily until at least 2007–08, according to the National Health and Nutrition Examination Survey (NHANES).

You Might Also Like
  • Prevalence of Gout and Hyperuricemia Increase in U.S.
  • Hyperuricemia Doesn’t Always Indicate Gout in Rheumatic Disease
  • Research Is Advancing Our Understanding of Gout & Hyperuricemia

Using 2007–2016 data from NHANES, a nationally representative survey of American men and women, Chen-Xu et al. set out to estimate the current prevalence rates and decadal trends of gout and hyperuricemia in the U.S., as well as the prevalence of urate-lowering therapy (the receipt of allopurinol, febuxostat or probenecid, either alone or in combination) among gout patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Methods: Using data from 5,467 participants in the NHANES 2015–16, the researchers estimated the most recent prevalence rates of gout and hyperuricemia. When the NHANES was conducted, all participants were asked about their history of gout (as diagnosed by a health professional) and medication use. Hyperuricemia was defined as having a serum urate level of >7.0 mg/dL in men and >5.7 mg/dL in women. The researchers examined decadal trends in these estimates using data from the NHANES 2007–16 and investigated urate-lowering therapy usage trends using the NHANES 2007–14 (the most recent data available to date).

Results: In 2015–16, the prevalence of gout was 3.9% among adults in the U.S. (9.2 million people), with 5.2% [5.9 million] in men and 2.7% [3.3 million] in women. Mean serum urate levels were 6.0 mg/dL in men and 4.8 mg/dL in women, and hyperuricemia prevalence rates were 20.2% and 20.0%, respectively. The prevalence of gout increased with age, with the lowest gout prevalence (0.7% or 0.6 million) in individuals ages 20–39 years and the highest (8.7% or 1.0 million) in individuals age 80 years or older. The prevalence of gout among Medicare-eligible individuals (age 65 years or older) was 8.6%, which corresponds to an estimated 4.0 million U.S. adults with gout. The prevalence rates of gout and hyperuricemia remained stable between 2007 and 2016 (P for trend >0.05). The prevalence of urate-lowering therapy use among patients with gout was 33% in 2007–14 and remained stable over time (P for trend >0.05).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Crystal Arthritis Tagged With: Arthritis & Rheumatology, Gout, Gout Resource Center, hyperuricemia, urate-lowering therapies

You Might Also Like:
  • Prevalence of Gout and Hyperuricemia Increase in U.S.
  • Hyperuricemia Doesn’t Always Indicate Gout in Rheumatic Disease
  • Research Is Advancing Our Understanding of Gout & Hyperuricemia
  • FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.